Aims: To assess the efficacy and safety of twice-daily insulin degludec/insulin aspart (IDegAsp) versus biphasic insulin aspart 30 (BIAsp 30) twice daily, both ± metformin, in Chinese adults (N = 543) with type 2 diabetes (T2D) inadequately controlled on premixed/self-mixed or basal insulin ± metformin. 
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| INTRODUCTION
Type 2 diabetes (T2D) is a progressive disorder characterized by increasing deficiency in insulin secretion and insulin resistance. In China, the disease burden of diabetes is high and increasing. 1 A survey of >170 000 Chinese people, undertaken in 2013 (when the population of China numbered 1.36 billion), estimated an overall prevalence of 10.9% for diabetes and 35.7% for prediabetes. 2, 3 It is estimated that diabetes prevalence in China will increase to 11.6%
(119 753 800 people) by the year 2045. 4 Diabetes currently accounts for 34% of deaths among Chinese people under the age of 60 years. 1 Type 2 diabetes is treated using a stepwise approach, starting with lifestyle management and progressing to oral antidiabetic treatments and injectable glucagon-like peptide-1 receptor agonists (GLP-1RAs)
or insulin, to prevent micro-and macrovascular tissue damage caused by chronic hyperglycaemia. [5] [6] [7] Insulin therapy is required for patients with T2D who are unable to achieve glycaemic control with oral antidiabetic medications or GLP-1RAs. [6] [7] [8] Premixed/self-mixed insulin comprises both a basal and bolus component, provides stable fasting and postprandial glycaemic control, and is an attractive alternative to classical basal-bolus therapy as fewer daily injections are required. 9 In most Asian countries, one of the most frequently prescribed insulin treatment regimens for both insulin initiation and intensification is twice-daily premixed/self-mixed insulin. 10 A 2017 retrospective database analysis of Chinese patients showed that premixed insulin was prescribed in 77.3% of those initiating insulin therapy 11 ; however, the majority of Chinese patients receiving insulin treatment exhibit inadequate glycaemic control. 2 Postprandial hyperglycaemia is more common in Asian than European populations; this is probably attributable to a combination of factors, including higher carbohydrate consumption, higher glycaemic response to carbohydrates, and poorer β-cell function, resulting in greater glucose intolerance in Asian populations. [12] [13] [14] [15] [16] Premixed insulin provides postprandial glycaemic control with the bolus component, in addition to the basal component, thereby meeting the needs of Asian populations.
Currently available premixed/self-mixed insulin products only offer intermediate-acting protaminated insulins as the basal component. This is because the previously available long-acting basal insulins (insulin glargine and insulin detemir) cannot be mixed with a rapidacting insulin because the formulation of insulin glargine is incompati- [24] [25] [26] [27] This phase III, randomized trial (NCT02762578) was performed to assess the efficacy and safety of IDegAsp twice daily compared with BIAsp 30 twice daily, both ± metformin, as an intensification regimen for Chinese adults with T2D inadequately controlled on once-daily or twice-daily premixed/self-mixed or basal insulin ± metformin.
| MATERIALS AND METHODS

| Trial design
This 26-week, phase III, open-label, treat-to-target, 2:1 randomized trial was conducted at 40 sites in China, in adults with inadequately controlled T2D. A list of participating investigators is available (Table S1 ). A web-based randomization system was used to allocate participants to receive IDegAsp twice daily or BIAsp 30 twice daily. In accordance with local health authority regulations, the trial population was randomized 2:1 to ensure that at least 300 participants received
IDegAsp twice-daily treatment, and to provide additional information on safety outcomes. The study was conducted according to the Declaration of Helsinki and its amendments, and Good Clinical Practice guidelines. 28 All participants provided written informed consent prior to any trial-related activities.
| Trial population
Men and women (age ≥ 18 years) with clinically diagnosed T2D for ≥6 months and receiving once-daily or twice-daily premixed/selfmixed or basal insulin ± metformin, were enrolled in the trial. All participants had to be on a treatment regimen unchanged for ≥8 weeks prior to randomization, and had to have a central laboratory-assessed glycated haemoglobin (HbA1c) concentration of 53 to 86 mmol/mol 
| Trial endpoints
The primary objective of the study was to compare and confirm the Supportive secondary efficacy endpoints were: percentage of participants achieving HbA1c <53 mmol/mol (<7.0%); mean SMBG profiles; and time to reach the titration target. Supportive secondary safety endpoints were: incidence of severe hypoglycaemic episodes; insulin dose after 26 weeks of treatment; and adverse events (AEs).
The primary, confirmatory secondary, and supportive secondary efficacy endpoint analyses were based on all randomized participants (full analysis set). Supportive secondary safety endpoints were analysed using data from all participants exposed to at least one dose of treatment (safety analysis set). inferiority (for change in HbA1c) or superiority (for a confirmatory secondary endpoint) was not confirmed in an analysis, then superiority assessments lower in the hierarchy could not be performed, irrespective of any P value obtained. Endpoint results were analysed using an analysis of variance model with treatment, antidiabetic therapy at screening, and sex as fixed factors, and age and baseline response as covariates; estimated treatment differences (ETDs) were assessed using a one-sided P value test. The rate of hypoglycaemic episodes was analysed using a negative binomial model with a log-link function and the logarithm of the time period, in which a hypoglycaemic episode was considered treatment-emergent as offset.
| Definition of hypoglycaemia
Missing values were imputed using last observed value.
3 | RESULTS
| Patient disposition and baseline characteristics
Of the 702 adults screened, 543 were randomized 2:1 to receive either IDegAsp twice daily (n = 361) or BIAsp 30 twice daily (n = 182), and 541 were exposed to treatment (Figure 1 
| Fasting plasma glucose
The observed mean FPG levels at week 26 were lower in the IDegAsp 
| Hypoglycaemic episodes
The observed rates of nocturnal confirmed hypoglycaemic episodes per 100 participant-years of exposure (PYE) were 34. confirmed and total confirmed hypoglycaemic episodes were observed between treatment groups for the first 8 weeks of the study, after which the groups diverged, with a higher number of epi- 
| Body weight
An increase in body weight was seen in both treatment groups, with an estimated least squares (LS) mean (SE) change from baseline to 
| Self-measured blood glucose
The estimated mean of the nine-point SMBG profile at week 26 was (Table S3 ).
| Time to reach titration target
The time (weeks) to first achieve a titration target SMBG of 4.0 to 
| Severe hypoglycaemic episodes
No severe hypoglycaemic episodes were recorded in the IDegAsp group, whereas six participants (3.3%) in the BIAsp 30 group reported nine severe hypoglycaemic episodes corresponding to a rate of 10.36 episodes per 100 PYE (Table 2 ). Among participants who had received BIAsp 30 twice daily, three (1.7%) had a total of four episodes of nocturnal severe hypoglycaemia, with a rate of 4.61 episodes per 100 PYE ( Table 2) . Rates of nocturnal and total confirmed hypoglycaemic episodes are shown in the 'Primary and confirmatory endpoints' section.
| Insulin dose
At baseline, both treatment groups received similar mean insulin doses (Table 1) 
| Adverse events
Overall AE rates (number of AEs per 100 PYE) were comparable between treatment groups (321.74 for IDegAsp twice daily vs. 348.82
for BIAsp 30 twice daily), demonstrating that both treatments were well tolerated (Table S4) 
| DISCUSSION
IDegAsp is the first soluble coformulation of an ultra-long-acting basal and rapid-acting bolus insulin (70:30). It is intended to increase treatment adherence and convenience, leading to improved long-term glycaemic control and a reduction in complications relating to chronic hyperglycaemia. 20 Compared with BIAsp 30 twice-daily, IDegAsp
T A B L E 2 Summary of hypoglycaemic episodes
IDegAsp twice daily (n = 360) BIAsp 30 twice daily (n = 181) Estimated treatment ratio (95% CI) a n (%) E R n (%) E R twice daily demonstrated non-inferiority with respect to change in In the present study, plasma glucose values were self-measured by patients at specific time intervals using finger-prick testing; a con- 
